Publications
Detailed Information
Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyung Soon | - |
dc.contributor.author | Kim, Joon Ye | - |
dc.contributor.author | Ro, Simon Weonsang | - |
dc.contributor.author | Kim, Myoung Soo | - |
dc.contributor.author | Kim, Hae Ryoung | - |
dc.contributor.author | Joo, Dong Jin | - |
dc.date.accessioned | 2023-01-09T00:24:52Z | - |
dc.date.available | 2023-01-09T00:24:52Z | - |
dc.date.created | 2022-11-16 | - |
dc.date.issued | 2022-11 | - |
dc.identifier.citation | Yonsei Medical Journal, Vol.63 No.11, pp.1007-1015 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://hdl.handle.net/10371/188895 | - |
dc.description.abstract | Purpose: We investigate whether low-dose rapamycin is effective in preventing hepatocellular carcinoma (HCC) growth and treating HCC after tumor development in transgenic mice.Materials and Methods: We established transgenic mice with HCC induced by activated HrasG12V and p53 suppression. Trans -genic mice were randomly assigned to five experimental groups: negative control, positive control, tacrolimus only, rapamycin only, and tacrolimus plus rapamycin. The mice were further divided into two groups according to time to commencement of im-munosuppressant treatment: de novo treatment and post-tumor development.Results: In the de novo treatment group, marked suppression of tumor growth was observed in the rapamycin only group. In the post-tumor development group, the rapamycin only group displayed no significant suppression of tumor growth, compared to the positive control group. In T lymphocyte subset analysis, the numbers of CD4+ effector T cells and CD4+ regulatory T cells were significantly lower in the positive control, tacrolimus only, and tacrolimus plus rapamycin groups than the negative control group. Immunohistochemical analysis revealed significantly higher expression of phosphorylated-mTOR, 4E-BP1, and S6K1 in the posi-tive control group than in the rapamycin only group.Conclusion: Low-dose rapamycin might be effective to prevent HCC growth, but may be ineffective as a treatment option after HCC development. | - |
dc.language | 영어 | - |
dc.publisher | 연세대학교의과대학 | - |
dc.title | Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.3349/ymj.2022.0247 | - |
dc.citation.journaltitle | Yonsei Medical Journal | - |
dc.identifier.wosid | 000877098800005 | - |
dc.identifier.scopusid | 2-s2.0-85140324081 | - |
dc.citation.endpage | 1015 | - |
dc.citation.number | 11 | - |
dc.citation.startpage | 1007 | - |
dc.citation.volume | 63 | - |
dc.identifier.kciid | ART002888403 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Hae Ryoung | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.